Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
BERLIN:NVV1
NVV1 Stock Chart & Stats
€6.70
-€1.01(-9.65%)
At close: 4:00 PM EST
€6.70
-€1.01(-9.65%)
Day’s Range― - ―
52-Week Range€4.82 - €11.31
Previous CloseN/A
Volume7.16K
Average Volume (3M)3.00
Market Cap
$1.08B
Enterprise ValueN/A
Total Cash (Recent Filing)$762.89M
Total Debt (Recent Filing)$251.14M
Price to Earnings (P/E)3.0
Beta2.51
Next Earnings
Mar 04, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding162,421,650
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-1.96
Price to Sales (P/S)1.79
P/FCF Ratio-12.20
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$9.83Price Target Upside46.71% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNovavax reported total revenues of $70.4M, compared to consensus estimated revenue of $42M.
Operational EfficiencyThe transaction with AstraZeneca is anticipated to generate savings of approximately $230M over the next 11 years, enhancing operational efficiency.
Vaccine DevelopmentNovavax is on-track to receive a $125M milestone payment following the initiation of the Phase 3 CIC study.
Bears Say
Commercialization HurdlesSanofi's commercialization of the Nuvaxovid COVID-19 vaccine may face hurdles to meaningful revenue growth near-term with a restricted US label and continued rocky COVID sentiment.
Market Share DeclineIn the 2025-26 vaccination season, Nuvaxovid had an average ~0.7% share from Week 1 to Week 8, representing a meaningful decline in market share.
Regulatory ChallengesThe ACIP committee's focus on clinical/shared decision making and informed consent may pose additional barriers to vaccine uptake.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €4.82 and its highest was €11.31 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.08B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2026 which is in 116 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 06, 2025. The company reported -€1.08 earnings per share for the quarter, missing the consensus estimate of -€1.034 by -€0.047.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.37.
How many shares outstanding does Novavax have?
Novavax has 162,421,650 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€1.08 in its last earnings report, missing expectations of -€1.034. Following the earnings report the stock price went up 3.398%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.83 (46.71% Upside)
$9.83 (46.71% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 80%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.51%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€9.83
▲(46.71% Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---